0001557939-16-000081.txt : 20160503 0001557939-16-000081.hdr.sgml : 20160503 20160503070013 ACCESSION NUMBER: 0001557939-16-000081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20160503 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160503 DATE AS OF CHANGE: 20160503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acelity L.P. Inc. CENTRAL INDEX KEY: 0001557939 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 981022387 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-184233-14 FILM NUMBER: 161613569 BUSINESS ADDRESS: STREET 1: 12930 IH 10 WEST CITY: SAN ANTONIO STATE: TX ZIP: 78249 BUSINESS PHONE: 2102556898 MAIL ADDRESS: STREET 1: 12930 IH 10 WEST CITY: SAN ANTONIO STATE: TX ZIP: 78249 FORMER COMPANY: FORMER CONFORMED NAME: Centaur Guernsey L.P. Inc. DATE OF NAME CHANGE: 20120911 8-K 1 a2016q18-kearningsrelease.htm 8-K 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 3, 2016


ACELITY L.P. INC.
(Exact name of registrant as specified in its charter)

Guernsey
 
333-184233-14
 
98-1022387
(State or other jurisdiction of incorporation or organization)
 
Commission File Number
 
(I.R.S. Employer Identification No.)

12930 West Interstate 10
San Antonio, Texas 78249
(Address of principal executive offices)

Registrant's telephone number, including area code: (210) 524-9000

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







Item 2.02. Results of Operations and Financial Condition
Acelity L.P. Inc. is reporting its financial results for the three months ended March 31, 2016. The report is attached hereto and incorporated herein by reference.
The information in this Item, including Exhibit 99.1, is being furnished, not filed. Accordingly, the information set forth in this Item will not be incorporated by reference into any registration statement filed by Acelity L.P. Inc., under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

Item 9.01. Financial Statements and Exhibits
(d) Exhibits
The following exhibits are filed with this Form 8-K:
Exhibit No.
 
Description
99.1
 
Acelity L.P. Inc. First Quarter Financial Results for 2016









SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ACELITY L.P. INC.
(REGISTRANT)
 
 
 
 
Date: May 3, 2016
 
By:
/s/ Brian Busenlehner
 
 
Name:
Brian Busenlehner
 
 
Title:
Authorized Signatory





EXHIBIT INDEX
Exhibit No.
 
Description
99.1
 
Acelity L.P. Inc. First Quarter Financial Results for 2016





 EX-99.1 2 a9912016q1earningsrelease.htm EXHIBIT 99.1 ACELITY L.P. INC. FIRST QUARTER FINANCIAL RESULTS FOR 2016 Exhibit



ACELITY L.P. INC. REPORTS
FIRST QUARTER FINANCIAL RESULTS FOR 2016
Total Revenue for the First Quarter of 2016 Grows 3.0% on a Constant Currency Basis


First Quarter Financial Highlights

•
Revenue for the first quarter of 2016 of $451.4 million, grew 1.6% as reported on a GAAP basis and 3.0% on a constant currency basis, from the prior-year period

•
Revenue from Advanced Wound Therapeutics ("AWT") grew 0.5% as reported on a GAAP basis and 2.1% on a constant currency basis, led by solid volume growth in advanced wound devices compared to the prior-year period

•
Revenue from Regenerative Medicine ("RM") grew 5.5% as reported on a GAAP basis and 5.8% on a constant currency basis, due primarily to higher volumes associated with breast reconstruction procedures

•
Net loss was $26.0 million, as reported on a GAAP basis, up from $4.5 million net loss in the prior-year period, due primarily to the impact of foreign currency exchange rate movements on the revaluation of our Term E-1 EURO loan

•
Adjusted EBITDA1 of $161.0 million, declined 2.9% as reported from the prior-year period and 2.2% on a constant currency basis primarily due to investments being made in our franchise structure and sales force to drive growth


Operational Highlights

•
The Company refinanced its Senior Term E-2 Credit Facility due November 4, 2016 with the proceeds from the offering of $400.0 million of 7.875% First Lien Senior Secured Notes due 2021.  Additionally, the Company extended a portion of its Revolving Credit Facility by one year to November 4, 2017.

•
Announced a partnership with Mediq to exclusively distribute Acelity’s advanced wound care and regenerative medicine portfolio in Denmark, Finland, Norway and Sweden. The alliance with Mediq, a leading homecare and medical device delivery company, offers Acelity access to Mediq’s specialized knowledge, expertise and network in the region and allows Acelity to expand operations in the post-acute environment.


Joe Woody, President and Chief Executive Officer, commented, “We begin 2016 with significant momentum, having achieved our sixth consecutive quarter of organic revenue growth driven by strong volumes in advanced wound devices, significant growth in sales of expansion products, and double digit growth in revenue from breast reconstruction procedures. Looking ahead to the remainder of the year, we will continue to invest in our people, our innovation pipeline and our business to strengthen our unique therapeutic portfolio to deliver cost-effective solutions to patients around the world.”






Results of the first quarter ended March 31, 2016

Acelity first quarter revenue increased 1.6% as reported on a GAAP basis to $451.4 million, compared with $444.1 million last year. On a constant currency basis, revenue increased 3.0%.

•
AWT revenue was $339.0 million, up 0.5% as reported on a GAAP basis and 2.1% on a constant currency basis, compared to the prior-year period. Growth in AWT revenue was fueled primarily by increased volumes in advanced wound devices during the quarter and double-digit growth in expansion products, led by sales of Prevena™.

•
RM revenue was $109.9 million, up 5.5% as reported on a GAAP basis and 5.8% on a constant currency basis, compared to the prior-year period. The increase in RM revenue was primarily due to double digit growth in breast reconstruction procedures, partially offset by lower revenue from hernia repair procedures.

Net loss for the first quarter of 2016 was $26.0 million, as reported on a GAAP basis, compared to $4.5 million in the prior-year period. Adjusted EBITDA for the first quarter of 2016 decreased 2.9% to $161.0 million from $165.8 million in the prior-year period and decreased 2.2% on a constant currency basis. The decline in Adjusted EBITDA was attributable to investments being made in our franchise structure and sales force to drive growth, partially offset by revenue growth and expense savings associated with our integration and business optimization efforts.


Financial Position

Total cash at March 31, 2016, was $223.6 million. During the first quarter of 2016, Acelity generated cash of $78.2 million from operations, used cash of $19.6 million in investing activities and generated cash of $73.6 million from financing activities.

On February 9, 2016, we issued $400.0 million aggregate principal amount of 7.875% First Lien Senior Secured Notes due 2021. We used a portion of the proceeds from the issuance of the First Lien Notes to repay all amounts outstanding under our Senior Term E-2 Credit Facility due November 4, 2016, together with accrued interest and related fees and expenses.

On February 9, 2016, we entered into Amendments No. 7 and No. 8 to our Senior Secured Credit Facility to, among other things, extend the maturity date of certain consenting lenders’ commitments under the Revolving Credit Facility. After giving effect to these amendments, we continue to have $200.0 million of aggregate revolving loan commitments under our Revolving Credit Facility with $28.7 million of the commitments maturing on November 4, 2016, and $171.3 million maturing on November 4, 2017.

As of March 31, 2016, total long-term debt outstanding was $4.842 billion and our Net Leverage Ratio2 was 6.5x.


Company Structure

Acelity is a leading global medical technology company committed to the development and commercialization of advanced wound care and regenerative medicine solutions. Acelity was formed by uniting the strengths of three organizations, KCI, Systagenix and LifeCell, into our two business segments: Advanced Wound Therapeutics and Regenerative Medicine. Our mission is to change the clinical practice of medicine with solutions that speed healing, reduce complications, create economic value and improve patients’ lives. Acelity is controlled by investment funds advised by Apax Partners LLP and Apax Partners L.P. and controlled affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board and certain other co-investors.  Unless otherwise noted in this report, the terms “we,” “our” or “Company,” refer to Acelity and its subsidiaries, collectively.





Non-GAAP Financial Information

The following provides information regarding non-GAAP financial measures used in this earnings release:

To supplement our consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), we have disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. A reconciliation of Adjusted EBITDA from continuing operations and Adjusted EBITDA to net loss is provided later in this earnings release. In addition, the Company presents certain of its financial results on a constant currency basis in addition to GAAP results. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. In this release, we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates.

Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of our business performance and are useful for period-over-period comparisons of the performance of our business. While management believes that these financial measures are useful in evaluating our business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly entitled measures reported by other companies. See "Reconciliation from GAAP to Non-GAAP" included within this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures.


1Adjusted EBITDA excludes the impact of merger-related expenses, foreign currency gains or losses, business optimization expenses and other expenses specified in the reconciliation within this release.

2 The Net Leverage Ratio represents Net Debt divided by Consolidated EBITDA for the last twelve months. Net Debt consists of total indebtedness including capital leases and other financing obligations, less cash and cash equivalents up to the greater of $300.0 million or 40% of Consolidated EBITDA for the last twelve months. Consolidated EBITDA, as defined in our senior secured credit agreement, represents Adjusted EBITDA plus “run rate” cost savings.


FOR MORE INFORMATION, CONTACT:
Investors
Caleb Moore
Office: (210) 255-6433
caleb.moore@acelity.com
 
Media
Cheston Turbyfill
Office: (210) 255-6696
media@acelity.com





ACELITY L.P. INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(dollars in thousands)
(unaudited)

 
Three months ended March 31,
 
2016
 
2015
 
% Change
Revenue:
 
 
 
 
 
Rental
$
170,099

 
$
172,839

 
(1.6
)%
Sales
281,267

 
271,211

 
3.7

Total revenue
451,366

 
444,050

 
1.6

 
 
 
 
 
 
Rental expenses
74,895

 
78,178

 
(4.2
)
Cost of sales
78,579

 
73,414

 
7.0

Gross profit
297,892

 
292,458

 
1.9

 
 
 
 
 
 
Selling, general and administrative expenses
164,444

 
147,763

 
11.3

Research and development expenses
13,978

 
14,678

 
(4.8
)
Acquired intangible asset amortization
42,202

 
45,877

 
(8.0
)
Operating earnings
77,268

 
84,140

 
(8.2
)
 
 
 
 
 


Interest income and other
107

 
147

 
(27.2
)
Interest expense
(108,552
)
 
(104,726
)
 
3.7

Loss on extinguishment of debt
(3,609
)
 
—

 
—

Foreign currency gain (loss)
(4,330
)
 
19,400

 
—

Derivative instruments loss
(682
)
 
(3,348
)
 
(79.6
)
Loss before income tax expense (benefit)
(39,798
)
 
(4,387
)
 
—

Income tax expense (benefit)
(13,823
)
 
144

 
—

Net loss
$
(25,975
)
 
$
(4,531
)
 
—
 %









ACELITY L.P. INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in thousands)

 
March 31,
2016
 
December 31,
2015
Assets:
(unaudited)
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
223,616

 
$
88,409

Accounts receivable, net
419,883

 
413,531

Inventories, net
188,800

 
181,309

Deferred income taxes
43,781

 
74,521

Prepaid expenses and other
29,864

 
34,985

Total current assets
905,944

 
792,755

 
 
 
 
Net property, plant and equipment
266,008

 
273,076

Deferred income taxes
24,262

 
29,909

Goodwill
3,406,475

 
3,405,823

Identifiable intangible assets, net
2,178,864

 
2,219,088

Other non-current assets
4,647

 
6,104

 
 
 
 
 
$
6,786,200

 
$
6,726,755

 
 
 
 
Liabilities and Equity:
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
52,666

 
$
57,910

Accrued expenses and other
420,204

 
373,440

Current installments of long-term debt
22,258

 
22,130

Income taxes payable
8,837

 
3,561

Deferred income taxes
113,595

 
113,595

Total current liabilities
617,560

 
570,636

 
 
 
 
Long-term debt, net of current installments, discount and debt issuance costs
4,820,113

 
4,720,363

Non-current tax liabilities
33,694

 
34,833

Deferred income taxes
698,471

 
760,737

Other non-current liabilities
34,609

 
37,021

Total liabilities
6,204,447

 
6,123,590

Equity:
 
 
 
General partner’s capital
—

 
—

Limited partners’ capital
597,389

 
622,899

Accumulated other comprehensive loss, net
(15,636
)
 
(19,734
)
Total equity
581,753

 
603,165

 
 
 
 
 
$
6,786,200

 
$
6,726,755










ACELITY L.P. INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

 
Three months ended March 31,
 
2016
 
2015
Cash flows from operating activities:
 
 
 
Net loss
$
(25,975
)
 
$
(4,531
)
Adjustments to reconcile net loss to net cash provided by operating activities:
 
 
 
Amortization of debt issuance costs and discount
10,107

 
9,968

Depreciation and other amortization
64,734

 
66,331

Loss on disposition of assets
576

 
678

Amortization of fair value step-up in inventory
164

 
—

Provision for bad debt
2,183

 
1,827

Loss on extinguishment of debt
3,609

 
—

Equity-based compensation expense
768

 
535

Deferred income tax benefit
(24,076
)
 
(11,971
)
Unrealized gain on derivative instruments
(2,812
)
 
(315
)
Unrealized loss (gain) on foreign currency
5,327

 
(32,429
)
Change in assets and liabilities:
 
 
 
Decrease (increase) in accounts receivable, net
(7,694
)
 
5,362

Increase in inventories, net
(416
)
 
(3,666
)
Decrease (increase) in prepaid expenses and other
5,121

 
(774
)
Increase (decrease) in accounts payable
(5,183
)
 
4,363

Increase in accrued expenses and other
49,438

 
56,048

Increase (decrease) in tax liabilities, net
2,314

 
11,525

Net cash provided by operating activities
78,185

 
102,951

 
 
 
 
Cash flows from investing activities:
 
 
 
Additions to property, plant and equipment
(17,467
)
 
(10,491
)
Increase in inventory to be converted into equipment for short-term rental
(983
)
 
(3,356
)
Dispositions of property, plant and equipment
2

 
—

Increase in identifiable intangible assets and other non-current assets
(1,129
)
 
(1,821
)
Net cash used by investing activities
(19,577
)
 
(15,668
)
 
 
 
 
Cash flows from financing activities:
 
 
 
Distribution to limited partners
—

 
(55
)
Settlement of profits interest units
(217
)
 
(517
)
Proceeds from first lien senior secured notes
400,000

 
—

Repayments of long-term debt and capital lease obligations
(317,731
)
 
(6,415
)
Debt issuance costs
(8,407
)
 
(6,256
)
Net cash provided (used) by financing activities
73,645

 
(13,243
)
Effect of exchange rate changes on cash and cash equivalents
2,954

 
(7,072
)
Net increase in cash and cash equivalents
135,207

 
66,968

Cash and cash equivalents, beginning of period
88,409

 
183,541

Cash and cash equivalents, end of period
$
223,616

 
$
250,509





ACELITY L.P. INC. AND SUBSIDIARIES
Reconciliation from GAAP to Non-GAAP
Supplemental Revenue Data
(dollars in thousands)
(unaudited)
 
Three months ended March 31,
 
GAAP % Change
 
Constant Currency % Change (1)
 
2016
 
2015 GAAP
 
 
 
GAAP
 
FX Impact
 
Constant
Currency
 
 
 
Advanced Wound Therapeutics revenue:
 
 
 
 
 
 
 
 
 
 
 
Rental
$
170,099

 
$
778

 
$
170,877

 
$
172,839

 
(1.6
)%
 
(1.1
)%
Sales
168,943

 
4,667

 
173,610

 
164,420

 
2.8

 
5.6

  Total
339,042

 
5,445

 
344,487

 
337,259

 
0.5

 
2.1

 
 
 
 
 
 
 
 
 
 
 
 
Regenerative Medicine revenue:
 
 
 
 
 
 
 
 
 
 
 
Sales
109,874

 
298

 
110,172

 
104,169

 
5.5

 
5.8

 
 
 
 
 
 
 
 
 
 
 
 
Other revenue:
 
 
 
 
 
 
 
 
 
 
 
Sales
2,450

 
144

 
2,594

 
2,622

 
(6.6
)
 
(1.1
)
 
 
 
 
 
 
 
 
 
 
 
 
Total revenue:
 
 
 
 
 
 
 
 
 
 
 
Rental
170,099

 
778

 
170,877

 
172,839

 
(1.6
)
 
(1.1
)
Sales
281,267

 
5,109

 
286,376

 
271,211

 
3.7

 
5.6

  Total
$
451,366

 
$
5,887

 
$
457,253

 
$
444,050

 
1.6
 %
 
3.0
 %
 
 
 
 
 
 
 
 
 
 
 
 
(1) Represents percentage change between 2016 non-GAAP Constant Currency revenue and 2015 GAAP revenue.







ACELITY L.P. INC. AND SUBSIDIARIES
Reconciliation from GAAP to Non-GAAP
Selected Financial Information
(dollars in thousands)
(unaudited)

 
Three months ended March 31,
 
2016
 
2015
 
 
 
 
Net loss
$
(25,975
)
 
$
(4,531
)
Interest expense, net of interest income
108,451

 
104,651

Income tax expense (benefit)
(13,823
)
 
144

Foreign currency loss (gain)
4,330

 
(19,400
)
Depreciation and other amortization
64,734

 
66,331

Derivative instruments loss
682

 
3,348

Management fees and expenses
2,219

 
1,312

Equity-based compensation expense
768

 
535

Acquisition, disposition and financing expenses (1)
5,124

 
2,580

Business optimization expenses (2)
8,537

 
6,128

Other permitted expenses (3)
5,966

 
4,738

Adjusted EBITDA
$
161,013

 
$
165,836

 
 
 
 
Adjusted EBITDA as a percentage of revenue
35.7
%
 
37.3
%
 
 
 
 
(1) Represents labor, travel, training, consulting and other costs associated with acquisition, disposition and financing activities, such as the issuance of new notes, the amendment of our senior secured credit facility and technology acquisitions.
(2) Represents labor, travel, training, consulting and other costs associated exclusively with our business optimization initiatives.
(3) Represents charges for other permitted expenses as defined under our Senior Secured Credit Facility.


 
 
 
As Reported % Change
 
Constant Currency % Change (1)
 
2016
 
2015
 
 
 
As Reported
 
FX Impact
 
Constant
Currency
 
As Reported
 
 
Three months ended March 31,
 
 
 
 
 
 
 
 
 
 
 
Adjusted EBITDA
$
161,013

 
$
1,104

 
$
162,117

 
$
165,836

 
(2.9
)%
 
(2.2
)%
 
 
 
 
 
 
 
 
 
 
 
 
(1) Represents percentage change between 2016 Constant Currency EBITDA and 2015 As Reported EBITDA.






 GRAPHIC 3 acelitycompaniesaa05.jpg begin 644 acelitycompaniesaa05.jpg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end GRAPHIC 4 acelitylogoaa05.jpg begin 644 acelitylogoaa05.jpg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